Singapore trial explores tolerance-building therapy for prawn allergies

Prawn allergies present particular challenges for residents of Singapore and Southeast Asia, where shellfish features prominently in everyday cooking and dining. Unlike those in regions where prawns are occasional menu items, people with prawn allergies here must navigate constant dietary restrictions and cross-contamination risks in shared kitchens and restaurants.

Researchers in Singapore are now testing whether oral immunotherapy—a technique involving controlled, incremental exposure to allergens—could help prawn-allergic individuals develop tolerance over time. The approach has shown promise in managing other food allergies by gradually desensitizing the immune system to specific proteins.

The clinical trial represents an important step toward expanding treatment options beyond avoidance strategies. If successful, the therapy could significantly improve quality of life for the thousands of Singaporeans living with prawn allergies, allowing them greater flexibility in food choices and reducing anxiety around accidental exposure.

Oral immunotherapy requires careful medical supervision, as allergic reactions remain a risk during the exposure process. Researchers are closely monitoring trial participants to ensure safety while gathering data on the therapy's effectiveness in the local population.